(OPT-80-302) DEFLECT-1: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis Against CLostridium difficilE-Associated Diarrhea in Individuals Undergoing Hematopoietic Stem Cell Transplantation
Description: 

The objective of this study is to demonstrate the efficacy and safety of fidaxomicin versus placebo for prophylaxis against Clostridium difficile-Associated Diarrhea (CDAD) in adult subjects undergoing hematopoietic stem cell transplantation (HSCT).

Study Number: 

PH 225712

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01691248

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.